TAC-001 as a Promising Combination Partner for Cancer Vaccines

Time: 4:45 pm
day: Conference Day One


  • Introduction to Tallac’s platform of immune-targeted TLR9 agonist antibody conjugates
  • Introduction to TAC-001, a B-cell targeted TLR9 agonist antibody conjugate that triggers innate and adaptive anti-cancer immunity
  • Preclinical rationale for combining TAC-001 with cancer vaccines